Rallybio Executive Chairman Martin Mackay to resign employment, stay as Chairman and consultant

Rallybio Corp

Martin Mackay will resign as Executive Chairman and employee effective Dec 31, 2024; no severance paid.
He will remain as Chairman of the Board; consulting agreement from Jan 1, 2025 to Jan 1, 2026 at $18,750/month.
Outstanding unvested time-based equity awards will vest immediately upon a Change of Control during consultancy.
Dr. Mackay eligible for 2024 annual bonus based on performance, paid at same time as employees.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Martin Mackay

Executive Chairman

RLYB · Rallybio Corp

Effective: 2024-12-31
Filed: July 23, 2024, 7:59 PM ET

On July 23, 2024, Martin Mackay, Ph.D., informed the Board of Directors (the Board) of Rallybio Corporation (Rallybio) that he will resign his Executive Chairman role and his employment with Rallybio, effective December 31, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Martin Mackay resigned as Executive Chairman at Rallybio Corp.

Action: resigned
Role: Executive Chairman

Exact text from the filing

On July 23, 2024, Martin Mackay, Ph.D., informed the Board of Directors (the Board) of Rallybio Corporation (Rallybio) that he will resign his Executive Chairman role and his employment with Rallybio, effective December 31, 2024.

View on SEC.gov

Rallybio Corp filing history →

Source: SEC EDGAR

accession 0001739410-24-000105

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.